Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022005174 - FUSION PROTEIN COMPRISING ANTI-LAG-3 ANTIBODY AND IL-2, AND USE THEREOF

Publication Number WO/2022/005174
Publication Date 06.01.2022
International Application No. PCT/KR2021/008198
International Filing Date 29.06.2021
IPC
C07K 16/28 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 14/55 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
54Interleukins (IL)
55IL-2
A61K 38/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61K 39/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/55
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
54Interleukins [IL]
55IL-2
C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Applicants
  • (주)지아이이노베이션 GI INNOVATION, INC. [KR]/[KR]
Inventors
  • 장명호 JANG, Myung Ho
  • 조영규 CHO, Young-Gyu
  • 오영민 OH, Young Min
  • 심예인 SHIM, Yaein
Agents
  • 류종우 RYU, Jong Woo
  • 이내영 LEE, Rae Young
Priority Data
10-2020-007997830.06.2020KR
Publication Language Korean (ko)
Filing Language Korean (KO)
Designated States
Title
(EN) FUSION PROTEIN COMPRISING ANTI-LAG-3 ANTIBODY AND IL-2, AND USE THEREOF
(FR) PROTÉINE DE FUSION COMPRENANT UN ANTICORPS ANTI-LAG-3 ET IL-2 ET SON UTILISATION
(KO) 항-LAG-3 항체 및 IL-2를 포함하는 융합단백질 및 이의 용도
Abstract
(EN) The present invention relates to a fusion protein comprising an anti-LAG-3 antibody and IL-2 or a variant thereof. In the fusion protein of the present invention, the anti-LAG-3 antibody portion binds to LAG-3 to control the bond between LAG-3 and MHCⅡ. Also, IL-2 protein or a variant thereof can control the activity of T cells. Therefore, a pharmaceutical composition comprising the fusion protein increases the immune activity in the body and thus can be used as an anticancer drug and is highly likely to be utilized on an industrial scale.
(FR) La présente invention concerne une protéine de fusion comprenant un anticorps anti-LAG-3 et IL-2 ou un variant de celle-ci. Dans la protéine de fusion selon la présente invention, la partie anticorps anti-LAG-3 se lie à LAG-3 pour contrôler la liaison entre LAG-3 et MHCII. De plus, la protéine IL-2 ou un variant de celle-ci peut réguler l'activité des lymphocytes T. Par conséquent, une composition pharmaceutique comprenant la protéine de fusion augmente l'activité immunitaire dans le corps et peut donc être utilisée en tant que médicament anticancéreux et est très susceptible d'être utilisée à une échelle industrielle.
(KO) 본 발명은 항-LAG-3 항체 및 IL-2 또는 이의 변이체를 포함하는 융합단백질에 관한 것이다. 본 발명의 융합단백질에서 항-LAG-3 항체 부분이 LAG-3와 결합하여 LAG-3와 MHCⅡ와의 결합을 조절할 수 있다. 또한, IL-2 단백질 또는 이의 변이체는 T 세포의 활성을 조절할 수 있다. 따라서, 상기 융합단백질을 포함하는 약학 조성물은 체내의 면역활성을 증가시켜 항암제로 이용 가능하여 산업적으로 활용 가능성이 높다.
Related patent documents
Latest bibliographic data on file with the International Bureau